leadf
logo-loader
viewSeelos Therapeutics

Seelos Therapeutics "extremely pleased" with side effect data from Phase I studies of SLS-002

Some of the key highlights of the interim vital signs adverse events data, included that no serious adverse events related to vital signs were observed

Seelos Therapeutics -
The SLS-002 drug candidate is aimed at treating acute suicidal ideation and behavior in patients with major depressive disorder and PTSD

Seelos Therapeutics Inc (NASDAQ:SEEL) continues to be "extremely pleased" with the side-effect profile of its SLS-002 drug candidate for acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and PTSD, the firm said, as it announced additional data from Phase 1 studies.

Some of the key highlights of the interim vital signs adverse events (AEs) data from the study, which involves 104 subjects, included that no serious adverse events (SAEs) related to vital signs were observed.

READ: Seelos to design Sanfilippo syndrome study of its drug Trehalose in Europe following regulatory guidance

The biopharma group also highlighted that, in the open-label study of SLS-002-101, only five out of 42 subjects, at a 60mg dose experienced mild and transient AEs. Increases in blood pressure and heart rate are known to be side effects of ketamine.

Additional data from the Phase I studies are expected to be released early in the second quarter of 2020 once all dose cohorts are unblinded and evaluated, the firm said.

Seelos also announced that it has completed its Type C meeting with the US Food and Drug Administration (FDA), as scheduled.

This meeting was to discuss the protocol design for a study of the SLS-002 candidate for ASIB in patients with Major Depressive Disorder (MDD).

"Earlier this month, we completed our scheduled face to face Type C meeting with the FDA for input and feedback on a potential clinical study of SLS-002 for acute suicidal ideation and behavior in patients with major depressive disorder,” Raj Mehra, the chairman and CEO of Seelos noted in the statement.

“We continue to be extremely pleased with the side effect profile of SLS-002 to date and will continue to work closely with the agency on the design of the protocol for the next study," he added.

Shares in New York nudged up 3.7% to $0.49.

Contact the author at giles@proactiveinvestors.com

Quick facts: Seelos Therapeutics

Price: 0.7804 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $41.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read